Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

Core Insights - Revolution Medicines has initiated the RASolute 304 trial, a Phase 3 clinical study evaluating daraxonrasib for patients with resectable pancreatic ductal adenocarcinoma (PDAC) who have undergone surgery and chemotherapy [1][3] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors [7] - The company's lead candidate, daraxonrasib (RMC-6236), is an oral, direct RAS(ON) multi-selective inhibitor aimed at treating various cancers driven by oncogenic RAS mutations [6][7] Clinical Trial Details - The RASolute 304 trial aims to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations, assessing the efficacy of daraxonrasib in improving disease-free survival compared to observation [2] - The primary endpoint of the trial is disease-free survival, with secondary endpoints including overall survival, safety, and tolerability [2] Industry Context - Pancreatic cancer is one of the most lethal malignancies, with around 60,000 new diagnoses and approximately 50,000 deaths annually in the U.S. [4] - The majority of PDAC patients (about 80%) are diagnosed at an advanced stage, contributing to a five-year survival rate of approximately 3% [5]